ReviewSeminars in immunology2025
Discovery and characterization of vertebrate sialoglycan-binding proteins.
Review in Seminars in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An atlas of human siglecs integrates expression, affinity, and cis/trans sialoglycan recognition profiles.Nature communications · 2026Article
- Writers and readers of sialylation in immunoregulation in cancer.The Journal of biological chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
All known life forms feature a dense ensemble of cell surface and extracellular glycans. In vertebrates this includes a high density of sialic acids (Sias), a family of acidic sugars typically capping glycans of cell surface or secreted glycoproteins and glycolipids. Since Sia was found to be the receptor for the influenza virus, many other pathogens have since been shown to recognize specific host sialoglycans as targets for their hemagglutinins, adhesins and toxins, often with remarkable specificity and high affinity/avidity. Other pathogens have evolved diverse mechanisms to evade host immunity by 'molecular mimicry' of host sialoglycans. Sialic acids also act as "biological masks", preventing access to underlying structures. Until the late 1970s, it was assumed that endogenous sialoglycan-binding proteins (SGBPs) did not exist in vertebrates. Several such vSGBPs have since been discovered, characterized by distinct sialoglycan specificities but generally low affinity. Markedly different rates of evolution and "Red Queen" effects likely explain this striking difference from the high specificity and affinity/avidity of numerous microbial SGBPs (mSGBPs). Nevertheless, these vSGBPs play important roles in normal development, physiology and disease conditions, with implications for human evolution. This review describes the discovery and characterization of vSGBPs. Most are previously known proteins, and their sialoglycan recognition had been discovered serendipitously. Thus, we may be seeing the 'tip of an iceberg' with many more such proteins to be discovered. We also emphasize recent studies showing that SGBP properties are markedly affected by competing endogenous Sialomes, such that in vitro studies may need to be re-visited, under conditions present in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.